AC Immune (NASDAQ:ACIU) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research note issued to investors on Friday,Benzinga reports. They currently have a $16.00 price objective on the stock.

AC Immune Trading Down 0.4 %

Shares of ACIU stock opened at $2.29 on Friday. AC Immune has a 1 year low of $2.19 and a 1 year high of $4.98. The firm’s fifty day simple moving average is $2.61 and its 200 day simple moving average is $2.98. The firm has a market capitalization of $226.57 million, a P/E ratio of -4.98 and a beta of 1.23.

Institutional Investors Weigh In On AC Immune

A number of institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new stake in shares of AC Immune in the 4th quarter valued at $118,000. Two Sigma Advisers LP acquired a new position in shares of AC Immune in the 4th quarter valued at approximately $36,000. Cantor Fitzgerald L. P. acquired a new position in shares of AC Immune in the 4th quarter valued at approximately $68,000. Jane Street Group LLC acquired a new position in shares of AC Immune in the 4th quarter valued at approximately $66,000. Finally, Northern Trust Corp acquired a new position in shares of AC Immune in the 4th quarter valued at approximately $1,088,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.